The US IPO market produced seven IPOs in January 2013—the busiest start to the year since 2006. Buoyed by the $2.2 billion IPO of Pfizer’s animal health unit Zoetis, gross proceeds in January were $3.3 billion—the highest January figure since 2000. The month included IPOs by well-established companies with proven revenue and profitability as well as a trio of biotech offerings.
The average first-day gain for January’s IPOs was 18% compared to 16% for all IPOs in 2012. Norwegian Cruise Line, Bright Horizons and Zoetis enjoyed first-day gains of 30%, 29% and 19%, respectively—these gains were all the more striking because each offering was priced above the range. There were no “broken” IPOs (IPOs whose stock closes below the offering price on their opening day) in the month.
With offerings by KaloBios Pharmaceuticals, LipoScience and Stemline Therapeutics during the last week of January, the biotech IPO market began the year with a solid start. LipoScience and Stemline rose 16% and 18%, respectively, in first-day trading while KaloBios was flat. Each of these IPOs priced at the bottom of the range.
The remaining January IPO was by Starwood-backed homebuilder TRI Pointe Homes, which saw a 12% first-day gain after pricing above the range.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
With corporate data security breaches on the rise, the NYDFS has adopted rules requiring financial institutions to take certain measures to safeguard their data and inform state regulators about cybersecurity incidents.
The United States District Court for the Southern District of Florida granted preliminary approval of a nearly $31 million FACTA class action settlement against Doctor's Associates, Inc., doing business as...
The New York State Department of Financial Services recently promulgated cyber regulations for financial institutions that are likely to increase the risks to directors & officers, resulting in an increase in claims.
One of the regulatory pillars of the EMIR is the requirement for parties to collateralize the marked-to-market exposure in over-the-counter derivatives transactions that are not cleared by a central clearing system.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).